**Question:** Treatment of post menopausal osteoporosis are all EXCEPT

A. Calcitonin
B. Alendronate
C. Estrogen therapy
D. Raloxifene

**Core Concept:** Post-menopausal osteoporosis is a condition characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to an increased risk of fracture. Treatment options aim to combat this condition and prevent further bone loss.

**Why the Correct Answer is Right:** Estrogen therapy (option C) is not typically used as a first-line treatment for post-menopausal osteoporosis due to concerns about potential side effects, such as breast cancer risk, endometrial cancer, and venous thromboembolism. Additionally, estrogen therapy is not available in oral formulations, which makes it less convenient for patients.

**Why Each Wrong Option is Incorrect:**

A. Calcitonin (option A) is a hormone that helps regulate calcium levels in the blood and has a bone-protective effect. However, it is not effective in preventing fractures in the long term and is not commonly used as a standalone treatment option.

B. Alendronate (option B) is a bisphosphonate, a class of medications that inhibit osteoclast activity and promote bone mineralization. Although alendronate is a common treatment option for osteoporosis, it is not considered as permissible as estrogen therapy for post-menopausal osteoporosis.

D. Raloxifene (option D) is a selective estrogen receptor modulator (SERM) that acts as a partial estrogen agonist in the bone and an antagonist in the breast and endometrium. While raloxifene is used for osteoporosis treatment, it is not as effective as estrogen therapy and is not typically used as a first-line treatment for post-menopausal osteoporosis.

**Clinical Pearl:** For optimal treatment of post-menopausal osteoporosis, estrogen therapy should be considered as the first-line treatment option due to its proven efficacy and reduced fracture risk. If estrogen therapy is contraindicated or not suitable, other treatments like bisphosphonates, denosumab, or hormone therapy with selective estrogen receptor modulators (SERMs) can be considered.

**Correct Answer:** Estrogen therapy (option C) is contraindicated in most cases but can be considered in patients with contraindications to bisphosphonates or selective estrogen receptor modulators (SERMs).

**Why Each Wrong Option is Incorrect:**

A. Calcitonin (option A) is a hormone involved in calcium regulation and has some anti-osteoporotic effect but is not as effective as estrogen therapy and has limited long-term use.

B. Alendronate (option B) is a bisphosphonate, which inhibits osteoclast activity, reducing bone resorption and promoting bone mineralization. It is effective in reducing fractures but is not as potent as estrogen therapy.

D. Raloxifene (option